1Tardif JC,Cote G,Lesperance J,et al.Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group[].New England Journal of Medicine The.1997
2Watanabe K,Sekiya M,Ikeda S,et al.Prevention effects of probucol on restenosis after percutaneous transluminal coronary angioplasty[].American Heart Journal.1996
3Keefe HJ,Stone GW,Mccallister BD,et al.Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty[].The American Journal of Cardiology.1996
4Kunishima T,Musha H,Eto F,et al.A randomized trial of aspirin versus cilostazol therapy after successful coronary stent inplantation[].Clinical Therapeutics.1997
5Takagi T,Yamamuro A,Tamita K,et al.Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study[].American Heart Journal.2003
6Okamoto S,Inden M,Setsuda M,et al.Effects of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty[].American Heart Journal.1992
7YokoiH,DaidaH,Kuwabara Y,et al.Effectiveness of an antioxidant in preventing restenosis after percutaneous translum inal coronary angioplasty: the ProbucolAngioplasty Restenosis Trial[].Journal of the American College of Cardiology.1997
8Tardiff JC,Gregoire J,Schwartz L,et al.Effects of AGI-1067 and probucol after percutaneous coronary interventions[].Circulation.2003
9Tardif JC,Grégoire J,L‘Allier PL, et al.Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial[].Atherosclerosis.2008
10Tsutsui M,Shimokawa H,Higuchi S,et al.Effect of cilostazol, a novel anti-platelet drug, on restenosis after percutaneous transluminal coronary angioplasty[].Japanese Circulation Journal.1996
3Lichtman JH, Froelicher ES, Blumenthal JA, et al. Depression as a risk factor for poor prognosis among patients with acute coronary: systematic review and recommendations: a scientific statement from the American Heart Association[J]. Circulation, 2014, 129(12): 1350-1369.
4Thombs BD, Bass EB, Ford DE, et al. Prevalence of depression in survivors of acute myocardial infarction[J]. J Gen Intern Med, 2006, 21(1): 30-38.
5Kuijpers PM, Hamulyak K, Strik JJ, et al. Beta-thromboglobulin and platelet factor 4 levels in post-myocardial infarction patents with maior del3ression[J]. Psychiatry Res. 2002. 109(2~: 207-210.
6Suh JW, Lee SP, Park KW, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol- based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial[J]. J Am Coil Cardiol, 2011, 57(3): 280-289.
8Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction[J]. Circulation, 2001, 104(16): 1894-1898.
9Serebruany VL, O'Connor CM, Gurbel PA. Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease[J]. Am J Cardiol, 2001, 87(12): 1398-1400.
10Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Human eytochromes and some newer antidepressants: kinetics, metabolism and drug interactions[J]. J Clin Psyehopharmaeol, 1999, 19(Suppl 1): 23-35.
